Important Safety Information
RITUXAN Access Solutions—Help with Insurance and Other Reimbursement Issues
At Genentech, we develop medicines for serious or life-threatening medical conditions and we believe medicines should be accessible to the patients who need them.
RITUXAN® Access Solutions™ provides insurance support—including coverage and reimbursement help—patient assistance and informational resources for both patients and their healthcare providers.
- Help with benefits and coverage issues
- Benefits investigation
- Prior authorization
- Recertification
- Help with reimbursement issues
- Appeals and denials
- Billing and coding information
- Support for uninsured and underinsured patients
- Referrals for co-pay assistance
- Product-specific patient assistance programs
- Access to treatment support programs
- Information tutorials
- MyAccessSolutions online system
- Medicare/Medicaid search tool
- Product spoilage and returns information
- Links to other websites
- Glossary of access and reimbursement terms
At RITUXAN Access Solutions, we're here to help find a way for you to get the medicine your doctor has prescribed, even if you have no insurance or have a problem paying for a Genentech medicine.
When you or your doctor's office call RITUXAN Access Solutions, you will connect with one of our experts, whose sole job is to make sure that you get the coverage or reimbursement help you need.
Contact RITUXAN Access Solutions
- Call 1-888-249-4918 (Monday-Friday, 6 am - 5 pm PST)
- Or visit www.RituxanAccessSolutions.com (24 hours a day, 7 days a week)
Genentech® Access to Care Foundation
The Genentech Access to Care Foundation was established to help qualified patients with unmet medical needs receive proper medical treatment. The Genentech Access to Care Foundation may be available to help those who are not able to obtain RITUXAN for financial reasons.
- If you have no insurance, or you are effectively uninsured because your health insurance plan denies you access to RITUXAN, you can apply to the Genentech Access to Care Foundation for help with your treatment
- We recognize the financial burdens that some patients and their families may experience in gaining access to our medicines. We are committed to assisting all eligible patients obtain access to our medicines, regardless of their ability to pay
- For eligible patients who are treated in the United States, the Genentech Access to Care Foundation will provide medicine to those who cannot afford to pay for it, because it is the right thing to do
This information does not take the place of talking with your doctor. Discuss with your doctor any questions you have about your medical condition or your treatment.
Indications and Important Safety Information
RITUXAN® (Rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
People with serious infections should not receive RITUXAN.
Important Safety Information:
- RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).
- RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.
- The most common side effects of RITUXAN seen in patients with non-Hodgkin’s lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.
- Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor
Please see full Prescribing Information, including Medication Guide.
